Injectable, spontaneously assembling, inorganic scaffolds modulate immune cells in vivo and increase vaccine efficacy

Nature Biotechnology

Volumn 33, Issue 1, 2015, Pages 64-72

  Kim, Jaeyun ^a,b,c   Li, Weiwei Aileen ^a,b   Choi, Youngjin ^c   Lewin, Sarah A ^b   Verbeke, Catia S ^a,b   Dranoff, Glenn ^d   Mooney, David J ^a,b  

^a HARVARD UNIVERSITY   (United States)

^b HARVARD UNIVERSITY   (United States)

^c Sungkyunkwan University   (South Korea)

^d HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ASPECT RATIO; BODY FLUIDS; CELLS; CYTOLOGY; ENZYME ACTIVITY; IMMUNE SYSTEM; MOBILE SECURITY; T-CELLS; TRANSPLANTATION (SURGICAL); VACCINES;

ADAPTIVE IMMUNE RESPONSE; CELLULAR MICROENVIRONMENT; HIGH ASPECT RATIO; MACROPOROUS STRUCTURES; MESOPOROUS SILICA; SURGICAL PROCEDURES; SUSTAINED RELEASE; VACCINE EFFICACIES;

SCAFFOLDS (BIOLOGY);

CPG OLIGODEOXYNUCLEOTIDE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; MESOPOROUS SILICA ROD; MOLECULAR SCAFFOLD; OVALBUMIN; UNCLASSIFIED DRUG; VACCINE;

ADAPTIVE IMMUNITY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DRUG FORMULATION; FEMALE; HELPER CELL; HOST CELL; IMMUNOCOMPETENT CELL; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; VACCINATION; ANIMAL; CYTOLOGY; IMMUNE SYSTEM; IMMUNOLOGY; TISSUE SCAFFOLD;

MUS;

ANIMALS; IMMUNE SYSTEM; MICE; TISSUE SCAFFOLDS; VACCINES;

EID: 84961289256     PISSN: 10870156     EISSN: 15461696     Source Type: Journal    
DOI: 10.1038/nbt.3071     Document Type: Article

References (50)

1. Jähnisch, H. et al. Dendritic cell-based immunotherapy for prostate cancer. Clin. Dev. Immunol. 2010, 517493 (2010).
2. Porter, D.L., Levine, B.L., Kalos, M., Bagg, A. & June, C.H. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N. Engl. J. Med. 365, 725-733 (2011).
3. Ali, O.A., Huebsch, N., Cao, L., Dranoff, G. & Mooney, D.J. Infection-mimicking materials to program dendritic cells in situ. Nat. Mater. 8, 151-158 (2009).
4. Ali, O.A., Emerich, D., Dranoff, G. & Mooney, D.J. In situ regulation of DC subsets and T cells mediates tumor regression in mice. Sci. Transl. Med. 1, ra19 (2009).
5. Stephan, M.T., Moon, J.J., Um, S.H., Bershteyn, A. & Irvine, D.J. Therapeutic cell engineering with surface-conjugated synthetic nanoparticles. Nat. Med. 16, 1035-1041 (2010).
6. Moon, J.J. et al. Interbilayer-crosslinked multilamellar vesicles as synthetic vaccines for potent humoral and cellular immune responses. Nat. Mater. 10, 243-251 (2011).
7. St. John, A.L., Chan, C.Y., Staats, H.F., Leong, K.W. & Abraham, S.N. Synthetic mast-cell granules as adjuvants to promote and polarize immunity in lymph nodes. Nat. Mater. 11, 250-257 (2012).
8. Park, J. et al. Combination delivery of TGF-β inhibitor and IL-2 by nanoscale liposomal polymeric gels enhances tumour immunotherapy. Nat. Mater. 11, 895-905 (2012).
9. Engelmayr, G.C. et al. Accordion-like honeycombs for tissue engineering of cardiac anisotropy. Nat. Mater. 7, 1003-1010 (2008).
10. Freed, L.E. et al. Biodegradable polymer scaffolds for tissue engineering. Biotechnol. (N.Y.) 12, 689-693 (1994).
11. Place, E.S., George, J.H., Williams, C.K. & Stevens, M.M. Synthetic polymer scaffolds for tissue engineering. Chem. Soc. Rev. 38, 1139-1151 (2009).
12. Lutolf, M. & Hubbell, J. Synthetic biomaterials as instructive extracellular microenvironments for morphogenesis in tissue engineering. Nat. Biotechnol. 23, 47-55 (2005).
13. Yamada, Y. et al. Autogenous injectable bone for regeneration with mesenchymal stem cells and platelet-rich plasma: tissue-engineered bone regeneration. Tissue Eng. 10, 955-964 (2004).
14. Yuen, W.W., Du, N.R., Chan, C.H., Silva, E.A. & Mooney, D.J. Mimicking nature by codelivery of stimulant and inhibitor to create temporally stable and spatially restricted angiogenic zones. Proc. Natl. Acad. Sci. USA 107, 17933-17938 (2010).
15. Xia, T. et al. Polyethyleneimine coating enhances the cellular uptake of mesoporous silica nanoparticles and allows safe delivery of siRNA and DNA constructs. ACS Nano 3, 3273-3286 (2009).
16. Kim, J. et al. Multifunctional uniform nanoparticles composed of a magnetite nanocrystal core and a mesoporous silica shell for magnetic resonance and fluorescence imaging and for drug delivery. Angew. Chem. Int. Ed. Engl. 47, 8438-8441 (2008).
17. Li, Z., Barnes, J.C., Bosoy, A., Stoddart, J.F. & Zink, J.I. Mesoporous silica nanoparticles in biomedical applications. Chem. Soc. Rev. 41, 2590-2605 (2012).
18. Garcia-Bennett, A.E. Synthesis, toxicology and potential of ordered mesoporous materials in nanomedicine. Nanomedicine 6, 867-877 (2011).
19. Petushkov, A., Ndiege, N., Salem, A.K. & Larsen, S.C. Toxicity of silica nanomaterials: Zeolites, mesoporous silica, and amorphous silica nanoparticles. Adv. Mol. Toxicol. 4, 223-266 (2010).
20. Zhao, D., Huo, Q., Feng, J., Chmelka, B.F. & Stucky, G.D. Nonionic triblock and star diblock copolymer and oligomeric surfactant syntheses of highly ordered, hydrothermally stable, mesoporous silica structures. J. Am. Chem. Soc. 120, 6024-6036 (1998).
21. Schmidt-Winkel, P., Yang, P., Margolese, D.I., Chmelka, B.F. & Stucky, G.D. Fluoride-induced hierarchical ordering of mesoporous silica in aqueous acid-syntheses. Adv. Mater. 11, 303-307 (1999).
22. Hudson, S.P., Padera, R.F., Langer, R. & Kohane, D.S. The biocompatibility of mesoporous silicates. Biomaterials 29, 4045-4055 (2008).
23. He, Q., Shi, J., Zhu, M., Chen, Y. & Chen, F. The three-stage in vitro degradation behavior of mesoporous silica in simulated body fluid. Microporous Mesoporous Mater. 131, 314-320 (2010).
24. Cauda, V., Schlossbauer, A. & Bein, T. Bio-degradation study of colloidal mesoporous silica nanoparticles: effect of surface functionalization with organo-silanes and poly (ethylene glycol). Microporous Mesoporous Mater. 132, 60-71 (2010).
25. Dieu, M. et al. Selective recruitment of immature and mature dendritic cells by distinct chemokines expressed in different anatomic sites. J. Exp. Med. 188, 373-386 (1998).
26. Randolph, G.J., Ochando, J. & Partida-Sánchez, S. Migration of dendritic cell subsets and their precursors. Annu. Rev. Immunol. 26, 293-316 (2008).
27. Steinman, R.M. The dendritic cell system and its role in immunogenicity. Annu. Rev. Immunol. 9, 271-296 (1991).
28. Banchereau, J. & Steinman, R.M. Dendritic cells and the control of immunity. Nature 392, 245-252 (1998).
29. Medzhitov, R. & Janeway, C.A. Jr. Innate immunity: impact on the adaptive immune response. Curr. Opin. Immunol. 9, 4-9 (1997).
30. Klinman, D.M. Immunotherapeutic uses of CpG oligodeoxynucleotides. Nat. Rev. Immunol. 4, 249-259 (2004).
31. Victora, G.D. & Nussenzweig, M.C. Germinal centers. Annu. Rev. Immunol. 30, 429-457 (2012).
32. Crotty, S. Follicular helper CD4 T cells (Tfh). Annu. Rev. Immunol. 29, 621-663 (2011).
33. Zhang, S. Fabrication of novel biomaterials through molecular self-assembly. Nat. Biotechnol. 21, 1171-1178 (2003).
34. Russell, B., Desai, T.A. & Goldspink, P. Temporal release of growth factors from 3d micro rod scaffolds for tissue regeneration. EP 2170419 A1 (2010).
35. Dostert, C. et al. Innate immune activation through Nalp3 inflammasome sensing of asbestos and silica. Science 320, 674-677 (2008).
36. Sharp, F.A. et al. Uptake of particulate vaccine adjuvants by dendritic cells activates the NALP3 inflammasome. Proc. Natl. Acad. Sci. USA 106, 870-875 (2009).
37. Hornung, V. et al. Silica crystals and aluminum salts activate the NALP3 inflammasome through phagosomal destabilization. Nat. Immunol. 9, 847-856 (2008).
38. Zhang, H. et al. Processing pathway dependence of amorphous silica nanoparticle toxicity: colloidal vs pyrolytic. J. Am. Chem. Soc. 134, 15790-15804 (2012).
39. Reddy, S.T. et al. Exploiting lymphatic transport and complement activation in nanoparticle vaccines. Nat. Biotechnol. 25, 1159-1164 (2007).
40. Meng, H. et al. Autonomous in vitro anticancer drug release from mesoporous silica nanoparticles by pH-sensitive nanovalves. J. Am. Chem. Soc. 132, 12690-12697 (2010).
41. Yang, P., Shili, G. & Jun, L. Functionalized mesoporous silica materials for controlled drug delivery. Chem. Soc. Rev. 41, 3679-3698 (2012).
42. Zou, W. Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat. Rev. Cancer 5, 263-274 (2005).
43. Rabinovich, G.A., Gabrilovich, D. & Sotomayor, E.M. Immunosuppressive strategies that are mediated by tumor cells. Annu. Rev. Immunol. 25, 267-296 (2007).
44. Moon, J.J. et al. Enhancing humoral responses to a malaria antigen with nanoparticle vaccines that expand Tfh cells and promote germinal center induction. Proc. Natl. Acad. Sci. USA 109, 1080-1085 (2012).
45. Zhang, X.Q. et al. Potent antigen-specific immune responses stimulated by codelivery of CpG ODN and antigens in degradable microparticles. J. Immunother. 30, 469-478 (2007).
46. Uto, T. et al. The induction of innate and adaptive immunity by biodegradable poly (γ-glutamic acid) nanoparticles via a TLR4 and MyD88 signaling pathway. Biomaterials 32, 5206-5212 (2011).
47. Hutchison, S. et al. Antigen depot is not required for alum adjuvanticity. FASEB J. 26, 1272-1279 (2012).
48. Lu, A., Schmidt, W., Spliethoff, B. & Schüth, F. Synthesis and characterization of nanocast silica NCS-1 with CMK-3 as a template. Chemistry 10, 6085-6092 (2004).
49. Faulkner, L., Buchan, G. & Baird, M. Interleukin-10 does not affect phagocytosis of particulate antigen by bonemarrow-derived dendritic cells but does impair antigen presentation. Immunology 99, 523-531 (2000).
50. Bhattacharya, P., Gopisetty, A., Ganesh, B.B., Sheng, J.R. & Prabhakar, B.S. GM-CSF-induced, bone-marrow-derived dendritic cells can expand natural Tregs and induce adaptive Tregs by different mechanisms. J. Leukoc. Biol. 89, 235-249 (2011).